{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:59:20Z","timestamp":1777492760908,"version":"3.51.4"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/19\/64\/34673"],"award-info":[{"award-number":["FS\/19\/64\/34673"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/19\/64\/34673"],"award-info":[{"award-number":["FS\/19\/64\/34673"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["PG\/18\/65\/33872"],"award-info":[{"award-number":["PG\/18\/65\/33872"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["PG\/18\/65\/33872"],"award-info":[{"award-number":["PG\/18\/65\/33872"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/19\/36\/34346"],"award-info":[{"award-number":["FS\/19\/36\/34346"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/19\/36\/34346"],"award-info":[{"award-number":["FS\/19\/36\/34346"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UKRI\u2019s Global Challenges Research Fund","award":["ES\/P011055\/1"],"award-info":[{"award-number":["ES\/P011055\/1"]}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004211","name":"Oxford Martin School, University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Randomised evidence on the efficacy of blood pressure (BP)-lowering treatment to reduce cardiovascular risk in patients with atrial fibrillation (AF) is limited. Therefore, this study aimed to compare the effects of BP-lowering drugs in patients with and without AF at baseline.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>The study was based on the resource provided by the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (BPLTTC), in which individual participant data (IPD) were extracted from trials with over 1,000 patient-years of follow-up in each arm, and that had randomly assigned patients to different classes of BP-lowering drugs, BP-lowering drugs versus placebo, or more versus less intensive BP-lowering regimens. For this study, only trials that had collected information on AF status at baseline were included. The effects of BP-lowering treatment on a composite endpoint of major cardiovascular events (stroke, ischaemic heart disease or heart failure) according to AF status at baseline were estimated using fixed-effect one-stage IPD meta-analyses based on Cox proportional hazards models stratified by trial. Furthermore, to assess whether the associations between the intensity of BP reduction and cardiovascular outcomes are similar in those with and without AF at baseline, we used a meta-regression. From the full BPLTTC database, 28 trials (145,653 participants) were excluded because AF status at baseline was uncertain or unavailable. A total of 22 trials were included with 188,570 patients, of whom 13,266 (7%) had AF at baseline. Risk of bias assessment showed that 20 trials were at low risk of bias and 2 trials at moderate risk. Meta-regression showed that relative risk reductions were proportional to trial-level intensity of BP lowering in patients with and without AF at baseline. Over 4.5 years of median follow-up, a 5-mm Hg systolic BP (SBP) reduction lowered the risk of major cardiovascular events both in patients with AF (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.83 to 1.00) and in patients without AF at baseline (HR 0.91, 95% CI 0.88 to 0.93), with no difference between subgroups. There was no evidence for heterogeneity of treatment effects by baseline SBP or drug class in patients with AF at baseline. The findings of this study need to be interpreted in light of its potential limitations, such as the limited number of trials, limitation in ascertaining AF cases due to the nature of the arrhythmia and measuring BP in patients with AF.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this meta-analysis, we found that BP-lowering treatment reduces the risk of major cardiovascular events similarly in individuals with and without AF. Pharmacological BP lowering for prevention of cardiovascular events should be recommended in patients with AF.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1003599","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T17:48:36Z","timestamp":1622569716000},"page":"e1003599","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9895-1493","authenticated-orcid":true,"given":"Ana-Catarina","family":"Pinho-Gomes","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-2937","authenticated-orcid":true,"given":"Luis","family":"Azevedo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-5241","authenticated-orcid":true,"given":"Emma","family":"Copland","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-9901","authenticated-orcid":true,"given":"Dexter","family":"Canoy","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-8874","authenticated-orcid":true,"given":"Milad","family":"Nazarzadeh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-8319","authenticated-orcid":true,"given":"Rema","family":"Ramakrishnan","sequence":"additional","affiliation":[]},{"given":"Eivind","family":"Berge","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-8454","authenticated-orcid":true,"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-9812","authenticated-orcid":true,"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-5296","authenticated-orcid":true,"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[]},{"given":"Koon","family":"Teo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-5673","authenticated-orcid":true,"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-0580","authenticated-orcid":true,"given":"John","family":"Chalmers","sequence":"additional","affiliation":[]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-4610","authenticated-orcid":true,"given":"Kazem","family":"Rahimi","sequence":"additional","affiliation":[]},{"name":"on behalf of the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"8","key":"pmed.1003599.ref001","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"SS Chugh","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"pmed.1003599.ref002","article-title":"Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care","volume":"6","author":"DA Lane","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"pmed.1003599.ref003","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"F Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"pmed.1003599.ref004","first-page":"162","article-title":"Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults","volume":"46","author":"CA Emdin","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"20","key":"pmed.1003599.ref005","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"E Marijon","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"pmed.1003599.ref006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","article-title":"Atrial fibrillation and the risk of myocardial infarction","volume":"174","author":"EZ Soliman","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"11","key":"pmed.1003599.ref007","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"P Kirchhof","year":"2016","journal-title":"Europace"},{"issue":"2","key":"pmed.1003599.ref008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/HJH.0b013e32834f03bf","article-title":"Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group \u2019Hypertension Arrhythmias and Thrombosis\u2019 of the European Society of Hypertension","volume":"30","author":"AJ Manolis","year":"2012","journal-title":"J Hypertens"},{"issue":"21","key":"pmed.1003599.ref009","first-page":"e1","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"CT January","year":"2014","journal-title":"JACC"},{"issue":"10022","key":"pmed.1003599.ref010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"D Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"pmed.1003599.ref011","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1136\/heartjnl-2018-314267","article-title":"Mechanisms of atrial fibrillation","volume":"105","author":"RS Wijesurendra","year":"2019","journal-title":"Heart"},{"issue":"10","key":"pmed.1003599.ref012","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"S Yusuf","year":"2011","journal-title":"NEJM"},{"issue":"5","key":"pmed.1003599.ref013","doi-asserted-by":"crossref","first-page":"e028698","DOI":"10.1136\/bmjopen-2018-028698","article-title":"Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (BPLTTC)","volume":"9","author":"K Rahimi","year":"2019","journal-title":"BMJ Open"},{"key":"pmed.1003599.ref014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"pmed.1003599.ref015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jclinepi.2003.12.001","article-title":"Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors","volume":"57","author":"CH Schmid","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"15","key":"pmed.1003599.ref016","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1002\/sim.2768","article-title":"Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data","volume":"26","author":"MC Simmonds","year":"2007","journal-title":"Stat Med"},{"issue":"6","key":"pmed.1003599.ref017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"PC Austin","year":"2016","journal-title":"Circulation"},{"issue":"9489","key":"pmed.1003599.ref018","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"B Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"9153","key":"pmed.1003599.ref019","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"L Hansson","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"pmed.1003599.ref020","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"T Ogihara","year":"2014","journal-title":"J Hypertens"},{"issue":"8","key":"pmed.1003599.ref021","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","article-title":"Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial","volume":"29","author":"M Matsuzaki","year":"2011","journal-title":"J Hypertens"},{"issue":"10","key":"pmed.1003599.ref022","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehp101","article-title":"Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)","volume":"30","author":"H Kasanuki","year":"2009","journal-title":"Eur Heart J"},{"issue":"9227","key":"pmed.1003599.ref023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"L Hansson","year":"2000","journal-title":"Lancet"},{"issue":"9192","key":"pmed.1003599.ref024","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"L Hansson","year":"1999","journal-title":"Lancet"},{"issue":"9426","key":"pmed.1003599.ref025","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"S Julius","year":"2004","journal-title":"Lancet"},{"issue":"15","key":"pmed.1003599.ref026","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"S Yusuf","year":"2008","journal-title":"NEJM"},{"issue":"9590","key":"pmed.1003599.ref027","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"A Patel","year":"2007","journal-title":"Lancet"},{"issue":"8442","key":"pmed.1003599.ref028","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(85)91783-0","article-title":"Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial","volume":"1","author":"A Amery","year":"1985","journal-title":"Lancet"},{"issue":"9080","key":"pmed.1003599.ref029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"JA Staessen","year":"1997","journal-title":"Lancet"},{"issue":"9644","key":"pmed.1003599.ref030","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"S Yusuf","year":"2008","journal-title":"Lancet"},{"issue":"17","key":"pmed.1003599.ref031","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"WC Cushman","year":"2010","journal-title":"NEJM"},{"issue":"9287","key":"pmed.1003599.ref032","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"issue":"23","key":"pmed.1003599.ref033","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"pmed.1003599.ref034","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"T Ogihara","year":"2014","journal-title":"J Hypertens"},{"issue":"9689","key":"pmed.1003599.ref035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","article-title":"Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial","volume":"374","author":"P Verdecchia","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"pmed.1003599.ref036","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1291\/hypres.27.181","article-title":"Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial","volume":"27","author":"Y Yui","year":"2004","journal-title":"Hypertens Res"},{"issue":"2","key":"pmed.1003599.ref037","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial","volume":"51","author":"T Ogihara","year":"2008","journal-title":"Hypertension"},{"issue":"33","key":"pmed.1003599.ref038","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"pmed.1003599.ref039","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2018050514","article-title":"Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"29","author":"N Bansal","year":"2018","journal-title":"JASN"},{"key":"pmed.1003599.ref040","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"A Odutayo","year":"2016","journal-title":"BMJ"},{"issue":"9921","key":"pmed.1003599.ref041","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"CT Ruff","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"pmed.1003599.ref042","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/STROKEAHA.115.009487","article-title":"Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial","volume":"46","author":"K Senoo","year":"2015","journal-title":"Stroke"},{"issue":"3","key":"pmed.1003599.ref043","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2016.0393","article-title":"Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation","volume":"1","author":"B Freedman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"3","key":"pmed.1003599.ref044","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"GY Lip","year":"2014","journal-title":"Europace"},{"issue":"6","key":"pmed.1003599.ref045","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"PK Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"pmed.1003599.ref046","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1097\/HJH.0b013e32835850d7","article-title":"Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis","volume":"30","author":"GS Stergiou","year":"2012","journal-title":"J Hypertens"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T17:49:46Z","timestamp":1622569786000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003599"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Lip","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003599","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}